Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Alerts On Adverse Reactions Of Aciclovir And Cephradine

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has alerted health care professionals, pharmaceutical manufacturers and distributors and the public about adverse reactions associated with antiviral aciclovir and antibiotic cephradine. According to figures from the National Center for ADR Monitoring, problems attributed to the two drugs - acute renal impairment and blood in urine - are still outstanding. SFDA reminds physicians to conduct full risk-benefit analysis when choosing drugs, paying especially close attention to the adverse effects caused by aciclovir and cephradine. The relevant manufacturers should conduct in-depth research into the mechanisms of the drug-caused impairment, evaluate the overall risk-benefit of the two medicines and adopt timely effective measures to reduce recurrence of adverse incidents in similar drugs. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069858

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel